Investment
Do you want to have a major impact on the development of our technology?
Invest in us!
A4F Fund
Investments are intended for qualified investors through our financial partner A4F Fund.
Investors Exit
We are preparing the project for exit to multinational investors according to established standards with leading experts.
Capital structure
P4P Technology has a clear capital structure with as few shareholders as possible.
Why invest in our future unicorn?
- There is a shortage of about 100 million litres of blood plasma in the world every year. That's a lot of potential for our solution!
- The intravenous application of Edestin opens up a separate market with multi-billion dollar potential.
- Demand for our solution will continue to grow as the society is getting older.
We are ready for clinical trials!
- Scientific studies have already confirmed the similarity between Albumin and Edestin. Now we need to send our blood plasma substitute into clinical trials.
- We can launch them within 8 months of the completion of the first investment round.
- Although clinical trials normally take ten years, chances are we won't need nearly that long.
- So far, we have managed to gain the trust of investors who have invested a total of 2,300,000 EUR in the project.
Edestin will become a global product. And maybe not only that!
We are also testing our technology for use in long-duration space missions, such as going to Mars. We're proving ourselves!